H Lévesque, J F Viallard, E Houivet, B Bonnotte, S Voisin, V Le Cam-Duchez, F Maillot, M Lambert, E Liozon, B Hervier, O Fain, B Guillet, J Schmidt, L E Luca, M Ebbo, N Ferreira-Maldent, A Babuty, L Sailler, P Duffau, V Barbay, S Audia, J Benichou, J Graveleau, Y Benhamou
BACKGROUND: Acquired hemophilia A (AHA) is a rare autoimmune disorder due to autoantibodies against Factor VIII, with a high mortality risk. Treatments aim to control bleeding and eradicate antibodies by immunosuppression. International recommendations rely on registers and international expert panels. METHODS: CREHA, an open-label randomized trial, compared the efficacy and safety of cyclophosphamide and rituximab in association with steroids in patients with newly diagnosed AHA...
March 15, 2024: Thrombosis Research